We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$841M
AUM Growth
-$257M
Cap. Flow
-$256M
Cap. Flow %
-30.4%
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$56.8M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12.1M
3
COGT icon
Cogent Biosciences
COGT
+$9.38M
4
INCY icon
Incyte
INCY
+$7.38M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.34M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$58.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.06M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.4M
4
MNKD icon
MannKind Corp
MNKD
+$3.35M
5
ABBV icon
AbbVie
ABBV
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 15.86%
2 Consumer Staples 0.43%
3 Consumer Discretionary 0.12%
4 Materials 0.09%
5 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNES icon
101
SenesTech
SNES
$7.11M
$405K 0.05%
17
+8
+89% +$257K
XTIA icon
102
XTI Aerospace
XTIA
$57.3M
– –
0
– –
ROSG
103
DELISTED
Rosetta Genomics Ltd.
ROSG
$383K 0.05%
+934,608
New +$453K
VIRX
104
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$380K 0.05%
40
+15
+60% +$2.57K
MRK icon
105
Merck
MRK
$326B
$374K 0.04%
+7,193
New +$388K
SSKN
106
DELISTED
Strata Skin Sciences
SSKN
$368K 0.04%
31,575
-1,936
-6% -$25.8K
BIOA
107
DELISTED
BioAmber Inc.
BIOA
$368K 0.04%
7,819,887
+7,798,568
+36,580% +$3.04M
XLRN
108
DELISTED
Acceleron Pharma
XLRN
$338K 0.04%
+8,646
New +$368K
AMRN
109
PUT
Amarin Corp
AMRN
$293M
$334K 0.04%
+55
New +$4.08K
TRAW icon
110
Traws Pharma
TRAW
$7.81M
$334K 0.04%
71
-29
-29% -$207K
XENE icon
111
Xenon Pharmaceuticals
XENE
$6.28B
$328K 0.04%
67,000
-262,400
-80% -$970K
EIGR
112
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$317K 0.04%
1,073
-560
-34% -$165K
INSM icon
113
Insmed
INSM
$22.6B
$300K 0.04%
+13,300
New +$350K
SNOA icon
114
Sonoma Pharmaceuticals
SNOA
$5.46M
$255K 0.03%
+384
New +$316K
NSPR icon
115
InspireMD
NSPR
$32.1M
$254K 0.03%
325
+160
+97% +$551K
FOCL
116
PUT
EDAP TMS S.A.
FOCL
$227M
$234K 0.03%
1,008
-432
-30% -$1.08K
MNKD icon
117
CALL
MannKind Corp
MNKD
$1.21B
$228K 0.03%
1,000
+884
+762% +$2.38K
XLRN
118
CALL
DELISTED
Acceleron Pharma
XLRN
$215K 0.03%
+55
New +$2.34K
AXSM icon
119
Axsome Therapeutics
AXSM
$12.1B
$199K 0.02%
+81,159
New +$243K
ONTXW
120
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$196K 0.02%
654,019
+10,775
+2% +$4.04K
SLDB icon
121
Solid Biosciences
SLDB
$785M
$188K 0.02%
+1,667
New +$563K
ABEO icon
122
Abeona Therapeutics
ABEO
$343M
$187K 0.02%
+520
New +$193K
IMGN
123
PUT
DELISTED
Immunogen Inc
IMGN
$173K 0.02%
+164
New +$1.62K
MRNS
124
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$172K 0.02%
+113
New +$2.69K
BPTH
125
DELISTED
Bio-Path Holdings Inc
BPTH
$170K 0.02%
213
-245
-53% -$191K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sabby Management withdrew a net $256M in Q1 2018, closing 75 positions and reducing 47 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $6.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 12% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Biogen worth $50.1M.

  • Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
  • Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
  • Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
  • Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
  • Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
  • Sabby Management opened 70 new positions and closed 75 in Q1 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.